Salivary Calprotectin as a Biomarker in Early Onset Inflammatory Bowel Disease: A Pilot Study
Authors:
- Simone LiguoriSLSimone Liguori
- Gennaro MusellaGennaro Musella
- Daniela AdamoDADaniela Adamo
- Erasmo MieleEMErasmo Miele
- Noemi CoppolaNCNoemi Coppola
- Federica CanforaFederica Canfora
- Carmela Del GiudiceCGCarmela Del Giudice
- Gianrico SpagnuoloGianrico Spagnuolo
- Sandro RengoSandro Rengo
- Michele Davide MignognaMMMichele Davide Mignogna
- Stefania LeuciStefania Leuci
Open Access
- 14 June 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4232
Abstract
Objectives: This study aimed to evaluate the potential of salivary calprotectin (SCP) as a novel biomarker in the management of Early Onset Inflammatory Bowel Disease (EOIBD), comparing EOIBD and healthy controls and differentiating patients based on their history of oral manifestations (OM). We correlated SCP and fecal calprotectin (FCP) in EOIBD and assessed the prognostic accuracy of SCP in predicting disease relapses. Methods: A sample of stimulated saliva was collected at baseline by 27 EOIBD and 9 healthy controls and then processed by ELISA for SCP determination. At sampling, a stool specimen was also provided by each patient for routine FCP assessment. Clinical disease activity was measured through Pediatric Ulcerative Colitis Activity Index (PUCAI) or Pediatric Crohn’s Disease Activity Index (PCDAI) at baseline and during follow-up at 4, 8 and 12 weeks. Results: A history of OM was described by 13 EOIBD. EOIBD with OM reported significantly higher SCP than EOIBD without OM (p < 0.01**) and controls (p < 0.05*). When evaluating the correlation between SCP and FCP in EOIBD with OM, positive FCP values (>120 mg/kg) were found to be associated with higher SCP concentrations (p < 0.05*), while in EOIBD without OM, a negative correlation was described (p < 0.05*). Lastly, EOIBD with OM who reported higher SCP were found to have significantly increased risk of relapse (p < 0.05*). Conclusions: In EOIBD with OM SCP was significantly more elevated and was correlated to intestinal inflammation and flare-up risk. Our results suggest the potential use of SCP as prognostic biomarker in children with intestinal and oral disease.Keywords
This publication has 49 references indexed in Scilit:
- Epidemiology of Pediatric Inflammatory Bowel DiseaseGastroenterology Clinics of North America, 2023
- The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven ColitisCell, 2020
- Salivary biomarkers in the context of gingival inflammation in children with cystic fibrosisJournal of Periodontology, 2020
- Salivary calprotectin is elevated in patients with active inflammatory bowel diseaseArchives of Oral Biology, 2019
- Levels of potential oral cancer salivary mRNA biomarkers in oral cancer patients in remission and oral lichen planus patientsClinical Oral Investigations, 2013
- Salivary levels of antimicrobial peptides Hnp 1-3, Ll-37 and S100 in Behcet's diseaseArchives of Oral Biology, 2012
- Preclinical validation of salivary biomarkers for primary Sjögren's syndromeArthritis Care & Research, 2010
- Pediatric Inflammatory Bowel Disease: Highlighting Pediatric Differences in IBDGastroenterology Clinics of North America, 2009
- Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDGastrointestinal Endoscopy, 2004
- Development and Validation of a Pediatric Crohn's Disease Activity IndexJournal of Pediatric Gastroenterology and Nutrition, 1991